Listed by the USPTO as ELENISTE, PIERRE PAUL
Tech Center 1600 • Art Units: 1622 1629
This examiner grants 35% of resolved cases
ELENISTE, PIERRE PAUL works in tech center 1600 and art unit 1622. The profile records 96 resolved cases, an allowance rate of 35.4%, and a median of 1314 days to allowance. Interviews are associated with a 31.1% lift in the allowance rate.
The allowance rate indicates that applicants should anticipate substantive prosecution work, while the median timeline supports planning for an extended path to allowance. The interview lift provides a practical reason to consider direct discussion where claim amendments or technical explanations could address the examiner’s concerns more efficiently than written submissions alone.
Nevakar Injectables Inc., Eli Lilly and Company, and Eisai R&D Management Co., Ltd. are the leading companies. Abel Schillinger, LLP, BANNER & WITCOFF, LTD., and COOLEY LLP are the leading firms. These participants show the prosecution contexts represented in the record.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17602718 | PROGRAMMABLE POLYMERIC DRUGS | Non-Final OA | SONY GROUP CORPORATION |
| 14443862 | SENSORILY ATTRACTIVE HYDRODISPERSION COMPRISING WAXES | Final Rejection | BEIERSDORF AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy35.4% of resolved applications examined by Pierre Paul Eleniste were allowed (96 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.
This examiner's interview lift is +31.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Pierre Paul Eleniste took 1,314 days on average from filing to allowance.
Pierre Paul Eleniste examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
